Related Experiment Videos
Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin
Araceli Cánovas1, Juan J Alonso, Guillermo Barreiro
1Department of Internal Medicine, Hospital de Cruces, Faculty of Medicine (UPV) Baracaldo, Vizcaya, Spain. aracelicanovas@telefonica.net
Aims And Background:
The Follicular Lymphoma International Prognostic Index (FLIPI) is a useful tool for the prognostic assessment of follicular lymphoma but beta-2 microglobulin (B2M) was not incorporated in this index. We aimed to compare the predictive value of B2M, FLIPI and other prognostic factors not included in the FLIPI index for overall survival (OS), complete remission (CR), and time to treatment failure (TTF) in a nonselected follicular lymphoma series.
Methods And Study Design:
Retrospective univariate and multivariate analysis of the prognostic value (for OS, CR, TTF) of B2M, FLIPI and other prognostic variables in follicular lymphoma was conducted in a cohort of follicular lymphoma patients between 1987 and 2007.
Results:
One hundred and six patients were studied. In univariate analysis B2M and B symptoms were significantly associated with OS, and FLIPI only detected two risk levels. In multivariate analysis of OS only two significant variables were found: FLIPI and B2M. Multivariate analysis of CR showed that normal B2M, absence of a bulky mass, uninvolved bone marrow, and chemotherapy with rituximab were significant predictors of CR. FLIPI (three levels), B2M, bone marrow infiltration, and chemotherapy with rituximab were significantly associated with TTF.
Conclusions:
We found a high predictive value of B2M for OS, CR, and TTF. B2M and FLIPI were the most important variables to predict OS. However, in our series FLIPI differentiated only between two mortality risk levels.
Insights
Beta-2 microglobulin (B2M) shows high predictive value for overall survival, complete remission, and time to treatment failure in follicular lymphoma patients. B2M and the Follicular Lymphoma International Prognostic Index (FLIPI) are key predictors of survival.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- The Follicular Lymphoma International Prognostic Index (FLIPI) is established for follicular lymphoma prognosis.
- Beta-2 microglobulin (B2M) is a potential prognostic marker not included in FLIPI.
Purpose of the Study:
- To compare the predictive value of B2M, FLIPI, and other factors for survival outcomes in follicular lymphoma.
- To evaluate B2M's role in predicting overall survival (OS), complete remission (CR), and time to treatment failure (TTF).
Main Methods:
- Retrospective analysis of 106 follicular lymphoma patients (1987-2007).
- Univariate and multivariate analyses assessed prognostic variables including B2M and FLIPI.
Main Results:
- B2M and B symptoms significantly predicted OS in univariate analysis.
- Multivariate analysis identified FLIPI and B2M as significant predictors of OS.
- B2M, FLIPI, bone marrow infiltration, and rituximab chemotherapy impacted TTF.
Conclusions:
- B2M demonstrates high predictive value for OS, CR, and TTF in follicular lymphoma.
- B2M and FLIPI are crucial for predicting OS, though FLIPI had limited risk stratification in this cohort.